These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3861196)

  • 41. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia.
    Stone RM; Spriggs DR; Dhawan RK; Arthur KA; Mayer RJ; Kufe DW
    Leukemia; 1990 Dec; 4(12):843-7. PubMed ID: 2243507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia.
    Fenaux P; Jouet JP; Bauters F
    J Clin Oncol; 1987 Jul; 5(7):1129-30. PubMed ID: 3474358
    [No Abstract]   [Full Text] [Related]  

  • 43. [Combined treatment of myeloid leukemia with cytosine arabinoside and 6-mercaptopurine].
    Lawkowicz W; Polubiec A; Domańska B
    Pol Tyg Lek; 1973 Jun; 28(23):865-7. PubMed ID: 4515923
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice.
    Berdel WE; Okamoto S; Danhauser-Riedl S; Hong CI; Winton EF; West CR; Rastetter J; Vogler WR
    Exp Hematol; 1989 May; 17(4):364-7. PubMed ID: 2707318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Yamauchi T; Negoro E; Arai H; Ikegaya S; Takagi K; Takemura H; Inai K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Anticancer Res; 2007; 27(4C):2635-9. PubMed ID: 17695426
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhancement of the cytotoxicity of cytosine arabinoside by interleukin-3.
    Tanaka M
    Jpn J Cancer Res; 1992 Feb; 83(2):194-9. PubMed ID: 1556000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis.
    Ray S; Bullock G; Nuñez G; Tang C; Ibrado AM; Huang Y; Bhalla K
    Cell Growth Differ; 1996 Dec; 7(12):1617-23. PubMed ID: 8959329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H; Breithaupt H
    Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of CML with blastic crisis by the combination therapy of VP and low-dose Ara-C].
    Chou T; Wakabayashi M; Hayashi N; Arakawa M
    Rinsho Ketsueki; 1992 Sep; 33(9):1263-7. PubMed ID: 1433949
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of cytosine arabinoside on the differentiation of granulocyte-monocyte progenitors (CFU-GM) and myeloid leukemia blasts (CFU-L) in vitro].
    Wächter M; Goldschmidt H; Blau W; Elstner E; Ihle R
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(6):927-34. PubMed ID: 2467864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes.
    Tricot G; De Bock R; Dekker AW; Boogaerts MA; Peetermans M; Punt K; Verwilghen RL
    Br J Haematol; 1984 Oct; 58(2):231-40. PubMed ID: 6591945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low doses of Ara-C in chronic myeloid leukemia in blastic transformation.
    Di Raimondo F; Guglielmo P; Milone G; Cacciola E; Giustolisi R
    Haematologica; 1985; 70(3):274-6. PubMed ID: 3932167
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of juvenile chronic granulocytic leukemia.
    Hiçsönmez G; Zamani V
    Turk J Pediatr; 1982; 24(3):189-91. PubMed ID: 6959407
    [No Abstract]   [Full Text] [Related]  

  • 57. Correlation of response to 1-beta-D-arabinofuranosyl cytosine and metabolism of drug by tumor.
    Gailani S; Nussbaum A
    J Med; 1976; 7(2):93-102. PubMed ID: 1064685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of Chronic Myeloid Leukemia in Advanced Phase.
    Bonifacio M; Stagno F; Scaffidi L; Krampera M; Di Raimondo F
    Front Oncol; 2019; 9():1132. PubMed ID: 31709190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of CML blast crisis with low dose ARA-C.
    di Raimondo F; Milone G; Guglielmo P; Cacciola E; Giustolisi R
    Br J Haematol; 1985 Aug; 60(4):773-4. PubMed ID: 3861196
    [No Abstract]   [Full Text] [Related]  

  • 60. 5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine.
    Galmarini CM; Cros E; Graham K; Thomas X; Mackey JR; Dumontet C
    Haematologica; 2004 May; 89(5):617-9. PubMed ID: 15136231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.